<DOC>
	<DOCNO>NCT01838512</DOCNO>
	<brief_summary>This non-interventional observational study aim understanding real world effectiveness novel agent use treat multiple myeloma impact patient-reported outcome . This study collect information already medical record regard treatment diagnostic procedure . Patients ask complete questionnaire patient-reported outcome measure .</brief_summary>
	<brief_title>Prospective Research Assessment Multiple Myeloma : An Observational Evaluation ( PREAMBLE )</brief_title>
	<detailed_description>This prospective , multi-regional , observational cohort study 3 year follow per patient . During entire observational period ( first patient first visit last patient last visit ) , vital status collect every 6 month patient , include complete 3-year follow prior study conclusion . The study include 3 cohort patient receive one follow class treatment MM : - IMiDs - Proteasome inhibitor - Combination novel therapy ( IMiD plus proteasome inhibitor ) - Additional use corticosteroid and/or cytotoxic agent ( eg , alkylating agent ) permit 3 cohort . Medicines prescribe manner consistent term approve market authorization line current standard practice participate physician allow . Note : Treatment current regimen : i. must initiate within 90 day consent study OR ii . case treatment yet initiate , documentation treatment strategy determine consent study must provide , treatment must initiate within 30 day consent . Enrollment approximately 1000 patient occur approximate 36-month timeframe , patient follow 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Alkylating Agents</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Patients diagnose relapsed refractory MM receive least one prior line therapy MM Age 18 year ( legal age consent ) old time entry study Have document progression prior line therapy Patients initiate treatment one follow therapy within 90 day consent study OR case treatment yet initiate , documentation treatment strategy determine consent study must provide , treatment must initiate within 30 day consent : IMiD* Proteasome inhibitor* Combination novel therapy ( IMiD plus proteasome inhibitor ) * Patients currently participate clinical trial MM Patients willing able provide inform consent Patients incarcerated Patients compulsory detention treatment physical ( eg , infectious ) psychiatric illness Patients currently receive treatment primary cancer multiple myeloma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>